Phaseline

Companies › Expedition Therapeutics

Expedition Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EXPD-101/FXS7553–Phase 2Chronic Obstructive Pulmonary Disease (COPD)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07684820EXPD-101/FXS7553Phase 2Chronic Obstructive Pulmonary Disease (COPD)RespiratoryJun 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma Jianmin Pharmaceutical Group Endeavor Biomedicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.